Sanofi (NASDAQ:SNY) said on Wednesday that it has decided to discontinue the phase 3 MOBILIZE trial evaluating riliprubart in ...

Sanofi SNY announced that it is discontinuing the phase III MOBILIZE study, which is evaluating its investigational drug, ...

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase 3 ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, ...

New research may redefine how chronic inflammatory demyelinating polyneuropathy is diagnosed. The study may help doctors more effectively diagnose and treat CIDP. New research from Jefferson Hospital ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated peripheral nerve disorder that is challenging to diagnose, particularly in the absence of reliable biomarkers. The goals ...

KING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage ...

Various clinical scores are available to assess the outcome of chronic inflammatory demyelinating polyneuropathy (CIDP), but these existing scales have some major limitations. A novel, simple scoring ...